American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
Year: 2021
Type: article
Abstract: Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated, with a few key statements as follows: in the first line setting, auto-HCT consolidation represents standard of care in eligible patients, whereas there is no clear role of allo-HCT or CAR T cell therapy outside of clinical trials. In the R/R setting, the preferential option is CAR T cell therapy, especially in patients with MCL failing or intolerant to at least one Bruton's tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T cell therapy fails or is infeasible. Several recommendations were based on expert opinion, where the panel developed consensus statements for important real-world clinical scenarios to guide clinical practice. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.
Authors: Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling, Brad Kahl, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Frederick L. Locke, Mazyar Shadman, Brian T. Hill, Sairah Ahmed, Alex F. Herrera, Craig S. Sauter, Veronika Bachanova, Nilanjan Ghosh, Matthew Lunning, Vaishalee P. Kenkre, Mahmoud Aljurf, Michael Wang, Kami J. Maddocks, John P. Leonard, Manali Kamdar, Tycel Phillips, Amanda F. Cashen, David J. Inwards, Anna Sureda, Jonathon B. Cohen, Sonali M. Smith, Carmello Carlo-Stella, Bipin Savani, Stephen P. Robinson, Timothy S. Fenske
Institutions: MedStar Georgetown University Hospital, Medical College of Wisconsin, University of South Florida, Heidelberg University, University of Rochester Medicine, University of Rochester, LMU Klinikum, Ludwig-Maximilians-Universität München, Washington University in St. Louis, Lund University, Skåne University Hospital, Mayo Clinic in Florida, Moffitt Cancer Center, University of Washington, Fred Hutch Cancer Center, Cleveland Clinic, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, City of Hope, Memorial Sloan Kettering Cancer Center, University of Minnesota, Levine Cancer Institute, University of Nebraska Medical Center, University of Wisconsin–Madison, King Faisal Specialist Hospital & Research Centre, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Weill Cornell Medicine, University of Colorado Cancer Center, University of Colorado Denver, University of Michigan, U-M Rogel Cancer Center, Mayo Clinic, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona, Winship Cancer Institute, University of Chicago, Humanitas University, IRCCS Humanitas Research Hospital, Vanderbilt University Medical Center, University Hospitals Bristol NHS Foundation Trust, Bristol NHS Foundation Trust
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Funders: U.S. Department of Defense, Genentech Foundation, Amgen, Bristol-Myers Squibb, Pfizer, Astellas Pharma US, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Roche, Sanofi, Leukemia and Lymphoma Society, Stanford University, Gilead Sciences, St. Baldrick's Foundation, Spectrum Pharmaceuticals, Celgene, AbbVie, Boston Children's Hospital, Karyopharm Therapeutics, Takeda Pharmaceuticals U.S.A., Dana-Farber Cancer Institute, CSL Behring, Actinium Pharmaceuticals, Jazz Pharmaceuticals, TG Therapeutics, Government of South Australia, Bayer Fund, Atara Biotherapeutics, Angiocrine Bioscience, bluebird bio, Adaptive Biotechnologies, BeiGene, Incyte, Omeros Corporation, Daiichi-Sankyo, Kiadis Pharma, Miltenyi Biotec, Astellas Pharma, MorphoSys, CytoSen Therapeutics, Aptitude Health, National Institutes of Health, Health Resources and Services Administration, Genentech, U.S. Public Health Service, U.S. Navy, Merck Sharp and Dohme, Biomedical Advanced Research and Development Authority, Sanofi Genzyme, Kite Pharma, Pharmacyclics, Legend Biotech, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases, Janssen Pharmaceuticals, Daiichi Sankyo Europe
Awards: G1244422278, Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients, G1360182821, G1387388519, Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors, G1664930879, DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE, G2322063371, G2551907125, G2585567822, G279418419, G3083416222, G3158753476, G345720138, G3464841971, G3540884004, G3699198379, G3700703953, G3745029439, G3869650085, G3928191929, G3985527170, G4314088951, G4334469717, G460283006, G4763906650, Cure Sickle Cell, G4867292856, G4898549738, G4905003149, G4910750673, G5039041663, G5079632146, G5186918478, G5233146051, G5236668762, G5356860631, G536687284, G541923634, G5478485217, G5636469388, G5735794559, DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE, G5804481516, G5843619112, G6079157135, G6238506038, G6283622733, G6463560129, G6636113147, G6659488911, G6932420423, G6979277618, G7121792964, G715986205, G7297870625, G7309478006, G7309481926, G746619137, G772836402, G7733677619, G7766946159, G7795396226, G7949979095, G7997008089, G8006577219, G8202316291, G8512811846, G8666848461, G8871973681, G8876996369, G8900316802, G9000004271, G9000065886, G9000066622, G9000165770, G9000211999, G9000227658, G9000232687, G9000293757, Molecular and Cellular Mechanisms of Chronic Myelomonocytic Leukemia (CMML), Immuno and Epigenetics of Hematopoietic Cell Transplantation, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.
OpenAlex ID: W3194788321